Surgical Margin Assessment by 3D Ultrasound

Sponsor
Rigshospitalet, Denmark (Other)
Overall Status
Recruiting
CT.gov ID
NCT05740774
Collaborator
(none)
7
1
1
3.9
1.8

Study Details

Study Description

Brief Summary

Complete removal of cancer encircled by a secure margin of healthy tissue is the aim of surgical oncology. A close or positive surgical margin reported by pathologist typically ends in adjuvant therapies (re-surgery and/or radiotherapy), which come with prognostic risks and financial cost. Therefore, ex-vivo imaging of removed cancer tissue may assist in margin evaluation. In this study, investigators aimed to investigate the correlation of 3D ultrasound to histopathology to assess tongue tumor margin status.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: 3D ultrasound
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
7 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Feasibility of 3D Ultrasound in the Assessment of Resection Margins During Surgery for Squamous Cell Carcinoma of the Tongue: a Comparison With Histopathology
Actual Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Mar 30, 2023
Anticipated Study Completion Date :
Apr 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tongue tumor resection

Diagnostic Test: 3D ultrasound
3D ultrasound scanning of the resected tongue tumor will be performed. The margin analysis will be made using the 3D ultrasound image.

Outcome Measures

Primary Outcome Measures

  1. Correlation of the surgical margin measurements of the 3D ultrasound to histopathology [2 weeks]

    The smallest margin will be measured in mm on 3D ultrasound image of the ex-vivo surgical specimen. Correlation of the measurement to the final histopathology result will be investigated.

  2. Diagnostic accuracy [2 weeks]

    number of margins correctly classified as free (> 5 mm), close (< 5 mm) or positive (<1 mm) margin

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with biopsy-proven oral tongue squamous cell carcinoma scheduled for surgical treatment

  • T1-T2 staging on cross-sectional imaging

Exclusion Criteria:
  • Age < 18 yrs

  • T3-T4 staging

  • Unable to understand the verbal or written information

  • Prior radiotherapy treatment of oral cavity cancer

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rigshospitalet København Ø Dk-015 Denmark 2100

Sponsors and Collaborators

  • Rigshospitalet, Denmark

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fatemeh Makouei, Biomedical Engineer, PhD, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT05740774
Other Study ID Numbers:
  • 21017915a
First Posted:
Feb 23, 2023
Last Update Posted:
Feb 23, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fatemeh Makouei, Biomedical Engineer, PhD, Rigshospitalet, Denmark
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2023